Multimodal Exercise Program on Parkinson's Disease Patients With Depression
Effectiveness of Multimodal Exercise Program on Depression and Health-Related Quality of Life in Patients With Parkinson's Disease
調査の概要
詳細な説明
Objective: Evaluate the effectiveness of a 8-week multimodal exercise program on depression and HRQOL in PD Patients.
Methods: Single-blinded, randomized controlled trial, from March 2016 to January 2017. Ninety-eight patients recruited to 2 groups: exercise group (n = 49) and control group (n = 49). The primary outcomes were depression and HRQOL; the secondary outcomes were activity of daily living, motor ability, fatigue, sleep quality and anxiety. Data collection at baseline, week 4 and 8 after intervention. Intervention were Multimodal Exercise Program, at least three times (30 - 50 minutes per section) a week or 10-15 minutes per section every day to accumulate 150 minutes a week for 8 weeks.
研究の種類
入学 (実際)
段階
- 適用できない
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- be diagnosed PD in Hoehn and Yahr stage I-II22
- under stable medication treatment at least 3 months
- no disease limiting the patient's ability to perform the exercises
Exclusion Criteria:
- severe cardiovascular disorders
- neuromusculoskeletal disorder
- cognitive impairment
- recent participation in any physiotherapy or rehabilitation program
- have exercise regularly
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし:control group
Control group maintained their regular lifestyle and received the routine care
|
|
|
実験的:exercise group
Participants in the exercise group (EG) were instructed to engage performed exercise at least 3 times per week (30-50 minutes) or 10-15 minutes per section every day to accumulate 150 minutes per week for 8 weeks using disc (DVD) at home.
Main exercise was moderate intensity aerobic exercise, an intensity of 55-70% of the heart rate reserve (HR max).
|
A step aerobics exercise lasted a total 30 minutes, including:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
GDS-15
時間枠:3 minutes
|
consisting of 15 questions, was the primary outcome evaluator (Sheikh and Yesavage, 1986).
Scores of 0-4 are considered to be normal; 5-8 indicates mild depression; 9-11 indicates moderate depression; and 12-15 indicates severe depression.
|
3 minutes
|
|
PDQ-8
時間枠:3 minutes
|
A sub-set of items is then selected from the PDQ-39 to create a shorter form version, the PDQ-8 (Jenkinson, Fitzpatrick & Peto, 1997).
The sum of the scores can provide a single figure used to assess the overall health-related quality of life profile of the individual questioned. .
Scores for each dimension range from 0 to 100, PDQ-8SI scores can be standardized on a scale from 0 to 100, with lower scores indicating better HRQoL.
|
3 minutes
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
UPDRS part II (ADL)
時間枠:5 minutes
|
The unified Parkinson's disease rating scale (UPDRS) is used to follow the longitudinal course of Parkinson's disease (Fahn & Elton, 1987).
The UPD rating scale is the most commonly used scale in the clinical study of Parkinson's disease.
A total of 199 points are possible (199 represents the worst disability and 0 no disability).
Part II: self-evaluation of the activities of daily life (ADLs).
The scales part 2: motor experiences of daily living (13 items), each subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe.
|
5 minutes
|
|
UPDRS part III (motor ability)
時間枠:10 minutes
|
The unified Parkinson's disease rating scale (UPDRS) is used to follow the longitudinal course of Parkinson's disease (Fahn & Elton, 1987).
The UPD rating scale is the most commonly used scale in the clinical study of Parkinson's disease.
Its 42 items are evaluated by interview and clinical observation.
The motor section in particular to follow the progression of a person's Parkinson's disease.
A total of 199 points are possible (199 represents the worst disability and 0 no disability).
The scales part 3: motor examination (18 items), each subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe.
|
10 minutes
|
|
Fatigue (FSS)
時間枠:5 minutes
|
The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue (Krupp, LaRocca, Muir-Nash, & Steinberg, 1989).
The subject is asked to read each statement and circle a number from 1 to 7, the items are scored on a 7 point scale with 1=strongly disagree and 7=strongly agree.
The minimum score=9 and maximum score possible=63.
Higher the score=greater fatigue severity.
|
5 minutes
|
|
Sleep quality (PSQI)
時間枠:5 minutes
|
The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep in adults (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989).
It differentiates "poor" from "good" sleep quality by measuring seven areas (components): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction over the last month.
A total score of "5" or greater is indicative of poor sleep quality.
|
5 minutes
|
|
Anxiety (HAS)
時間枠:3 minutes
|
The Hospital Anxiety Scale (HAS), a self-assessment scale, was developed to detect states of, anxiety and emotional distress, used to screen for the presence of anxiety, in a general medical population of patients (Zigmond & Snaith, 1983).
Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety.
For both scales, scores of less than 7 indicate normal, 8-10 indicate mild anxiety, 11-14 indicate moderate anxiety and 15-21 severe anxiety.
|
3 minutes
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
パーキンソン病の臨床試験
-
HuidaGene Therapeutics Co., Ltd.募集
-
Hemab ApSPSI CRO募集フォン・ヴィレブランド病(VWD) | フォン・ヴィレブランド病 (VWD)、タイプ 1 | フォンウィルブランド病(VWD)、タイプ2 | Von Willebrand Disease(VWD)、タイプ3 | フォン・ウィルブランド病、タイプ2a | Von Willebrand病、タイプ2M | Von Willebrand病、タイプ2Nアメリカ, イギリス, オーストラリア
-
Adelphi Values LLCBlueprint Medicines Corporation完了肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されましたアメリカ
exercise groupの臨床試験
-
National Taiwan Normal University完了
-
University of Erlangen-Nürnberg Medical SchoolKlinikum Nürnberg完了
-
Riphah International Universityまだ募集していません
-
Riphah International Universityまだ募集していません
-
University of TorontoUniversity Health Network, Toronto; University of Western Ontario, Canada; Institute for Clinical... と他の協力者完了
-
Mansoura Universityまだ募集していません